Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
Business Wire•12/10/2026•16:05 ET
0
Key Highlights
- ➤Savara (SVRA) secures CHEST 2026 oral presentation for Phase 3 IMPALA-2 data
- ➤Savara will present poster data on molgramostim in patients with mild diffusion impairment
- ➤Bruce C. Trapnell will present long-term efficacy and safety results from IMPALA-2
- ➤Savara will host an aPAP learning theatre with patients Eric and Karli
Expert Statements
Bruce C. Trapnell, Professor of Medicine and Pediatrics, University of Cincinnati College of Medicine
“Long-Term Efficacy and Safety of Molgramostim in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results From the IMPALA-2 Trial Open-Label Treatment Period”
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
-- Company to Host Learning Theatre on aPAP with Renowned Key Opinion Leader Along with Members of the Patient Community --
Get started
Create a free account to read the full story.